The Food and Drug Administration (“FDA”) recently announced that it planned to use different sources of data such as Reddit to better understand public health issues surrounding the use of cannabis derivatives, including delta-8 THC and CBD. In its published report, the FDA explained that it needed information about the potential adverse events and safety issues associated with FDA-regulated products, which include cannabis-derived products, commonly referred to as CDPs.
The agency also revealed that it needed data on the general patterns of emerging trends and product use so that it could deploy its limited resources effectively and quickly. This comes at a time when the CDP market is growing at a rapid pace, significantly outpacing the advancements made in science.
The agency believes that new approaches to identifying safety signals using rigorous analytical methods and different data sources will significantly contribute to the agency’s ability to respond to rapidly evolving product areas such as the cannabis-derived products market. The FDA also revealed that there are a series of projects in its feasibility assessment phase, one of which involves viewing consumer-generated content such as Reddit posts in order to determine issues that aren’t easily captured through conventional systems.
A separate project would entail comparing CBD product samples from the FDA database with certificates of analysis, in order to identify any issues with quality or inconsistencies. In addition to this, the FDA plans to develop a system that will find usage patterns and safety signals linked to emerging cannabis-derived products in real time. This includes a cannabinoid known as delta-8 THC, which the FDA warned people about because the agency has not yet evaluated the effectiveness or safety of the substance.
Other compounds the FDA is interested in learning more about include CBG (cannabigerol), THCV (tetrahydrocannabivarin), CBN (cannabinol) and delta-10 THC (delta-10 tetrahydrocannabinol).
At the start of this year, the FDA had announced that it would be taking the necessary steps required to fill the gaps in research on the effectiveness and safety of CBD. The agency explained that it was focused on improving CBD product identification, helping to develop a consumer register for CBD products, increasing product sampling in relation to reports of adverse effects, and assessing the best strategies for quality monitoring and safety of different types of CBD products.
In 2020, the agency released draft guidelines to streamline approvals for generic CBD medications. The FDA was also mandated under the appropriations bill to present an update on its regulatory approach to CBD. It provided the update in March 2020.
It would benefit the entire cannabis industry including sector actors such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) if such data collection results in clear regulatory guidelines for the CBD market and other related sectors.
NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.